Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM | The future role of CAR-T in pediatric ALL

Nirali Shah • 15 Oct 2021
COSTEM
Acute Lymphoblastic Leukemia Leukemia CAR-T

Nirali Shah, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD, shares her view on the future role of chimeric antigen receptor T-cells (CAR-T) in the treatment of pediatric acute lymphoblastic leukemia (ALL).This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Nirali Shah

1:31
Next steps for improving dual CARs
Nirali Shah • 15 Oct 2021
1:11
Managing infectious complications of CAR-T therapy
Nirali Shah • 15 Oct 2021
3:42
Prior blinatumomab use impacts CD19-CAR T-cell therapy response rates in R/R ALL
Nirali Shah • 25 Nov 2020
1:21
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
Nirali Shah • 9 Dec 2017

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals